Selected Publications

Academic Article

Year Title Altmetric
2022 PET/MRI in Pediatric Neuroimaging: Primer for Clinical PracticeAmerican Journal of Neuroradiology.  43:938-943. 2022
2022 Dynamic Amyloid PET: Relationships to 18F-Flortaucipir Tau PET MeasuresJournal of Nuclear Medicine.  63:287-293. 2022
2021 Utility of 18F-fluciclovine PET/MRI for staging newly diagnosed high-risk prostate cancer and evaluating response to initial androgen deprivation therapy: A prospective single-arm pilot studyAmerican Journal of Roentgenology.  217:720-729. 2021
2021 Production of [89Zr]Oxinate4 and cell radiolabeling for human useJournal of Labelled Compounds and Radiopharmaceuticals.  64:209-216. 2021
2021 Global access to medical imaging and nuclear medicineThe Lancet Oncology.  22:425-426. 2021
2021 Synchronous Malignancies Identified by 18F-fluciclovine Positron Emission Tomography for Prostate Cancer: Case Series and Mini-ReviewClinical Genitourinary Cancer.  19:e37-e40. 2021
2021 Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2Journal of Alzheimer's Disease.  79:543-557. 2021
2021 Real-Time Gain Control of PET Detectors and Evaluation with Challenging RadionuclidesIEEE Transactions on Medical Imaging.  40:71-80. 2021
2020 Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: Correlation with stereotactic histopathologyNeuro-oncology practice.  7:656-667. 2020
2020 Measurement of blood flow in myocardial layers: A step toward comprehensive physiological evaluationJournal of Nuclear Cardiology.  27:1675-1678. 2020
2020 Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT AmericasESC Heart Failure.  7:1676-1687. 2020
2020 FDG-PET/CT diagnosis of aortitis and pseudoaneurysmsJournal of Nuclear Cardiology.  27:362-365. 2020
2020 The role of metabolic plasticity in blood and brain stem cell pathophysiologyCancer Research.  80:5-16. 2020
2019 Myocardial blood flow measures using cardiac positron emission tomography: Software comparisonsJournal of Nuclear Cardiology.  26:2013-2017. 2019
2019 Heterogeneity Diffusion Imaging of gliomas: Initial experience and validationPLoS One.  14. 2019
2019 Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate CancerAdvances in Radiation Oncology.  4:649-658. 2019
2019 Recognizing and minimizing artifacts at ct, mri, us, and molecular imagingRadiographics.  39:1017-1018. 2019
2019 Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Workflow for Research and Clinical Brain PET Applications 2019
2019 Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0European Journal of Nuclear Medicine and Molecular Imaging.  46:540-557. 2019
2019 Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical CenterJournal of the American College of Radiology.  16:315-320. 2019
2019 Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET ApplicationsJournal of Alzheimer's Disease.  70:1241-1257. 2019
2019 Current and future imaging methods for evaluating response to immunotherapy in neuro-oncologyTheranostics.  9:5085-5104. 2019
2018 Imaging melphalan therapy response in preclinical extramedullary multiple myeloma with 18F-FDOPA and 18F-FDG PETJournal of Nuclear Medicine.  59:1551-1557. 2018
2018 Investigational PET tracers for high-grade gliomasThe Quarterly Journal of Nuclear Medicine and Molecular Imaging.  62:281-294. 2018
2018 Role of PET imaging for biochemical recurrence following primary treatment for prostate cancerTranslational andrology and urology.  7:S462-S476. 2018
2018 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumorsNeuro-oncology practice.  5:28-36. 2018
2018 PET/MR Imaging in Head and Neck Cancer: Current Applications and Future DirectionsMagnetic Resonance Imaging Clinics of North America.  26:167-178. 2018
2018 Amino acid uptake measured by [ 18 F]AFETP increases in response to arginine starvation in ASS1-deficient sarcomasTheranostics.  8:2107-2116. 2018
2018 Practical Considerations for Clinical PET/MR ImagingPET Clinics.  13:97-112. 2018
2017 Lymph node imaging in initial staging of prostate cancer: An overview and update.World Journal of Radiology.  9:389-399. 2017
2017 ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body.Journal of Nuclear Medicine.  58:1174-1176. 2017
2017 Evaluation of attenuation correction in cardiac PET using PET/MRJournal of Nuclear Cardiology.  24:839-846. 2017
2017 Practical Considerations for Clinical PET/MR ImagingMagnetic Resonance Imaging Clinics of North America.  25:281-296. 2017
2017 Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.Cell Reports.  18:991-1004. 2017
2017 Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein.Nature Communications.  8:14152. 2017
2016 Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?Nuclear Medicine and Molecular Imaging.  50:292-299. 2016
2016 18F-Fluciclovine (FACBC) and its potential use for breast cancer imagingJournal of Nuclear Medicine.  57:1329-1330. 2016
2016 Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis.Nuclear Medicine and Molecular Imaging.  50:228-239. 2016
2016 Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.JAMA Neurology.  73:1070-1077. 2016
2016 Clinical application of PET/MRI in oncologyJournal of Magnetic Resonance Imaging.  44:265-276. 2016
2016 Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphomaPediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI.  46:1258-1268. 2016
2016 SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.Journal of Nuclear Medicine.  57:1316-1322. 2016
2016 The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imagingBrain: a journal of neurology.  139:2249-2260. 2016
2016 Multimodality Review of Amyloid-related Diseases of the Central Nervous System.Radiographics.  36:1147-1163. 2016
2016 Impact of MR-Based Attenuation Correction on Neurologic PET Studies.Journal of Nuclear Medicine.  57:913-917. 2016
2016 Effect of α-Methyl versus α-Hydrogen Substitution on Brain Availability and Tumor Imaging Properties of Heptanoic [F-18]Fluoroalkyl Amino Acids for Positron Emission Tomography (PET)Journal of Medicinal Chemistry.  59:3515-3531. 2016
2016 PET/MRI: Emerging Clinical Applications in Oncology.Academic Radiology.  23:220-236. 2016
2015 Synthesis and Biological Evaluation of (S)-Amino-2-methyl-4-[76Br]bromo-3-(E)-butenoic Acid (BrVAIB) for Brain Tumor ImagingJournal of Medicinal Chemistry.  58:8542-8552. 2015
2015 PET/MRI for the body imager: abdominal and pelvic oncologic applications. 2015
2015 Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.Journal of Medicinal Chemistry.  58:3817-3829. 2015
2015 Imaging biomarkers associated with cognitive decline: a review.Biological Psychiatry.  77:685-692. 2015
2015 American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain.Journal of Nuclear Medicine.  56:642-645. 2015
2015 Beyond whole-body imaging: Advanced imaging techniques of PET/MRIClinical Nuclear Medicine.  40:e88-e95. 2015
2015 Facile purification and click labeling with 2-[18F]fluoroethyl azide using solid phase extraction cartridges.Tetrahedron Letters: the international journal for the rapid publication of all preliminary communications in organic chemistry.  56:952-954. 2015
2015 Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors.Disease Markers.  2015:874904. 2015
2015 System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.Nuclear Medicine and Biology.  42:8-18. 2015
2014 Attenuation Effects of MR Headphones During Brain PET/MR Studies.Journal of Nuclear Medicine Technology.  42:93-100. 2014
2014 An overview of nuclear medicine studies for urgent and emergent indications.Seminars in Roentgenology.  49:210-224. 2014
2014 Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET studyPsychiatry Research: Neuroimaging.  221:231-239. 2014
2014 Whole-body simultaneous positron emission tomography (PET)-MR: optimization and adaptation of MRI sequences.Journal of Magnetic Resonance Imaging.  39:259-268. 2014
2014 Imaging evaluation of CSF shunts.American Journal of Roentgenology.  202:38-53. 2014
2013 Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPETPLoS One.  8. 2013
2013 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.Journal of Nuclear Medicine.  54:1120-1126. 2013
2013 Radiolabeled amino acids for oncologic imaging.Journal of Nuclear Medicine.  54:1007-1010. 2013
2013 Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging.Nuclear Medicine and Biology.  40:498-506. 2013
2013 Overview of PET Tracers for Brain Tumor Imaging.PET Clinics.  8:129-146. 2013
2013 Nuclear medicine in the acute clinical setting: indications, imaging findings, and potential pitfalls.Radiographics.  33:375-396. 2013
2013 Advances in diagnostic testing for Alzheimer disease.Missouri medicine.  110:401-405. 2013
2013 Fluorine-18 labeled amino acids for oncologic imaging with positron emission tomography.Current Topics in Medicinal Chemistry.  13:871-891. 2013
2012 Commentary.Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine.  58:1190-1191. 2012
2012 Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents.Medicinal Research Reviews.  32:868-905. 2012
2010 Click synthesis and biologic evaluation of (R)- and (S)-2-amino-3-[1-(2-[18F]fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid for brain tumor imaging with positron emission tomography.Molecular Imaging.  9:329-342. 2010
2010 Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors.Journal of Medicinal Chemistry.  53:876-886. 2010
2008 Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography.Cancer and Metastasis Reviews.  27:555-573. 2008
2007 Preparation of antidepressants for use in preclinical research.International Journal of Neuropsychopharmacology.  10:759-763. 2007
2006 Evaluation of carbon-11-labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET.Journal of Medicinal Chemistry.  49:942-946. 2006
2005 Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies.Applied Radiation and Isotopes.  63:353-361. 2005
2005 Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents.Nuclear Medicine and Biology.  32:593-605. 2005
2005 Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.Journal of Medicinal Chemistry.  48:4254-4265. 2005
2005 Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography.Nuclear Medicine and Biology.  32:75-86. 2005
2004 Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter.Nuclear Medicine and Biology.  31:705-718. 2004
2004 Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.Journal of Medicinal Chemistry.  47:1122-1135. 2004
2003 Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids.Nuclear Medicine and Biology.  30:477-490. 2003
2003 Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis.Applied Radiation and Isotopes.  58:657-666. 2003
2003 Stereochemistry in Drug Action.Primary Care Companion to the Journal of Clinical Psychiatry.  5:70-73. 2003
2003 Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.Journal of Medicinal Chemistry.  46:925-935. 2003
2002 Radiolabeled amino acids for tumor imaging with PET: radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid.Journal of Medicinal Chemistry.  45:2240-2249. 2002
2002 Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection.Journal of Medicinal Chemistry.  45:2250-2259. 2002
2001 Radioligands for PET and SPECT Imaging of the central noradrenergic system.CNS Spectrums: the international journal of neuropsychiatric medicine.  6:704-709. 2001


Year Title Altmetric
2018 PET/MRI for clinical pediatric oncologic imaging.  401-432. 2018
2017 Overview of positron-emission tomography tracers for metabolic imaging.  47-80. 2017

Investigator On

  • Detecting Neuroinflammation in Fibromyalgia with the Positron Emission Tomography (PET) Radioligand [18] DPA-714  awarded by American Fibromyalgia Syndrome Association
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE R20-080  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: Role of Innate Immune Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 5: Innate and Adaptive Immunity in Lewy Body Dementia  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Measuring Neuroinflammation in Chronic Fatigue Syndrome with Whole-brain Magnetic Resonance Spectroscopy  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • Personalizing Immunotherapy in HER2+ Breast Cancer through Quantitative Imaging  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by NAVIDEA BIOPHARMACEUTICALS, INC.
  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^
  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^
  • Private Grant  awarded by Genzyme Corporation
  • Radiolabeled Antibodies Targeting LAT1 for Imaging and Therapy of Prostate Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer Immunotherapy  awarded by NIH - OFFICE OF THE DIRECTOR
  • UAB Alzheimer's Disease Research Center  awarded by National Institute on Aging/NIH/DHHS
  • UAB Alzheimer's Disease Research Center - Clinical Core  awarded by NIH - National Institutes of Health/DHHS
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Viability Testing of Immune Cells Extracted from Human Blood Samples  awarded by ME RESEARCH UK
  • Education And Training

  • Emory University SOM, Internship
  • Washington University SOM, Residency
  • Washington University SOM, Postdoctoral Fellowship
  • Doctor of Medicine, Emory University 2004
  • Doctor of Philosophy in Biological and Biomedical Sciences, Emory University 2003
  • Full Name

  • Jonathan McConathy